Malignant Mesothelioma Treatment Market - By Drug Class (Alkylating agents, Antimetabolites, Plant alkaloids, Antitumor Antibiotics, Others) By Application (Pleural Mesothelioma, Peritoneal Mesothelioma) By Region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America) - Industry Analysis, Opportunity and Forecast 2020 To 2027
Published Date: May 2021
No. of Pages: 183
Status: Published
Report Code: ARI100679
The global market for malignant mesothelioma therapy is expected to post a CAGR of nearly 7.5% in the 2020-2027 period.
The growing use of asbestos for commercial purposes is a key factor driving the development of the global market size of malignant mesothelioma therapies. Asbestos toxicity is the main risk factor for malignant mesothelioma. The use of asbestos has increased significantly over the years in various applications such as machinery, building materials, and vehicles for transportation. Thus, extensive use of asbestos for commercial purposes during the forecast period will drive the global market for malignant mesothelioma therapies. The growing awareness of malignant mesothelioma will have a positive impact on the market and significantly contribute to its growth over the forecast period.
Major players operating in the malignant mesothelioma market include Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Epizyme, Inc, Bayer AG, Aduro Biotech, Ono Pharmaceutical Co., Ltd., Polaris Pharmaceuticals, Inc., Calithera Biosciences, Inc., and CBT Pharmaceuticals, Inc.
The market for the treatment of mesothelioma is segmented into surgery, chemotherapy, targeted therapy and others based on the type of treatment.
Segment route of administration for the market in the treatment of mesothelioma is categorized into oral, parenteral, and other. The market for mesothelioma treatment is segmented into hospitals, homecare, specialty clinics and others, based on end-users. The market for mesothelioma treatment was divided into hospital pharmacy, online pharmacy, and retail pharmacy based on distribution channel.
Due to the increased prevalence of mesothelioma and the high availability of treatment options for patients suffering from mesothelioma, North America holds the major market share for mesothelioma treatment in the coming years. Europe's second growing regional segment is due to the increases that focus on research and development activity and advanced health care facilities supported by reimbursement policies. Due to the government funding and awareness, Asia-Pacific is expected to expand the market for mesothelioma treatment.
Analyst Commentary
Malignant mesothelioma can occur at any age, but is typical in adults 65 and older. It's more common in men than in women, the ratio male to female is 3:1. Malignant mesothelioma represents 1 per cent of all cancers around the world. Individuals exposed to asbestos (industrial pollutant) have an elevated risk of developing malignant mesothelioma. In contaminated areas, the risk of mesothelioma is increased by 2 to 10-fold when compared with non-polluted areas. In addition, people exposed to a high dose of radiation, zeolites (minerals chemically contaminated with asbestos), and those suffering from simian virus 40 infection may develop malignant mesothelioma.
The incidence of malignant mesothelioma has risen at a rapid pace all over the world over the years. This has led to a need for early-stage awareness-raising initiatives to diagnose and treat the disease. Consequently, several non-profit foundations and government agencies are taking initiatives to promote awareness among the population about malignant mesothelioma. The increasing awareness will increase the number of patients taking advantage of the treatment, which during the forecast period will positively influence the market for malignant mesothelioma therapeutics.
Segmentation
In terms of type, the malignant mesothelioma market may be segmented into malignant pleural mesothelioma (occurring in the lining of the lungs), malignant peritoneal mesothelioma (occurring in the lining of the abdomen), and malignant pericardial mesothelioma (occurring in the cardiac lining). The segment of malignant pleural mesothelioma is expected to grow because it accounts for 70% of all mesothelioma cases followed by malignant peritoneal mesothelioma which accounts for 15-20% of all mesothelioma cases. As regards treatment, the market for malignant mesothelioma can be segmented into surgery, chemotherapy, and radiotherapy.
Surgery requires pneumonectomy, debulking and omentectomy, and is recommended for malignant mesothelioma diagnosis. Patients that were successfully surgically resected have a high degree of monitoring (significantly 5 years). Radiation helps shrink the size of the tumor, and is also used as an adjuvant. In palliative care chemotherapy plays an significant function. A variety of companies including AstraZeneca are involved in research and development of malignant mesothelioma therapies. Big molecules in the pipeline include durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20 and 1716 HSV. In the near future, the therapeutic pipeline is expected to witness considerable growth in the malignant mesothelioma market due to higher incidence rates, increased air pollution, increased geriatric population and increased healthcare expenditure. Furthermore, the advancement of innovative therapy and the introduction of advance treatment options are likely to provide the malignant mesothelioma market with lucrative growth opportunities over the forecast period. Nonetheless, long latent periods between onset and symptom, lack of appropriate diagnosis and low surveillance levels are key factors that limit the demand for malignant mesotheliomas.
Regional Analysis
The malignant mesothelioma market can be segmented in terms of geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is leading the malignant mesothelioma market, followed by Europe due to the higher incidence and prevalence rate, rising geriatric population and increasing demand for advance treatment. Asia Pacific is a growing market for malignant mesothelioma due to the growth of healthcare facilities, patient awareness, and increased government spending in the healthcare sector. Poor awareness of patients, lack of proper treatment, and high therapy costs are factors that restrain the Middle East & Africa malignant mesothelioma market.
Pemetrexed and combination drug type category is the most attractive on the malignant mesothelioma market in Latin America and shows a consumer attractiveness index of 2.7. The segment is projected to hit the highest CAGR of 9.5 per cent and 7.5 per cent respectively in the APAC and MEA regional markets during the forecast period.
TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Engine Powered of Suppliers
3.7.2. Bargaining Engine Powered of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Malignant Mesothelioma Treatment Market
Chapter 5. Global Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
5.1. Global Malignant Mesothelioma Treatment Market Share, By Drug Class, 2015 - 2027 (USD Million)
5.1.1. ALKYLATING AGENTS
5.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. ANTIMETABOLITES
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. PLANT ALKALOIDS
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Antitumor Antibiotics
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.5. Others
5.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Malignant Mesothelioma Treatment Market Overview, By Application, 2015 - 2027 (USD Million)
6.1. Global Malignant Mesothelioma Treatment Market Share, By Application, 2015 - 2027 (USD Million)
6.1.1. Pleural Mesothelioma,
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. PERITONEAL MESOTHELIOMA
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Malignant Mesothelioma Treatment Market Overview, By Geography, 2015 - 2027 (USD Million)
7.1. Global Malignant Mesothelioma Treatment Market Share, By Geography, 2015 - 2027 (USD Million)
7.1.1. Market Size and projections, by Countries, 2015 - 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2020 & 2027 (%)
Chapter 8. North America Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1. North America Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.2. North America Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
8.1.3. North America Malignant Mesothelioma Treatment Market Overview, By Application, 2015 - 2027 (USD Million)
8.1.4. North America Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
8.1.4.1.3. Other Segments
8.1.4.2. Canada Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
8.1.4.2.3. Other Segments
8.1.4.3. Mexico Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
8.1.4.3.3. Other Segments
Chapter 9. Europe Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1. Europe Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.3. Europe Malignant Mesothelioma Treatment Market Overview, By Application, 2015 - 2027 (USD Million)
9.1.4. Europe Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.4.1.3. Others Segments
9.1.4.2. France
9.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.4.2.3. Others Segments
9.1.4.3. UK
9.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.4.3.3. Others Segments
9.1.4.4. Italy
9.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Malignant Mesothelioma Treatment Market Overview, By Drug Class 2015 - 2027 (USD Million)
9.1.4.4.3. Others Segments
9.1.4.5. Spain
9.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.4.5.3. Others Segments
9.1.4.6. Rest of Europe
9.1.4.6.1. Market size and projections, 2015 – 2025
9.1.4.6.2. Rest of Europe Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
9.1.4.6.3. Others Segments
Chapter 10. Asia Pacific Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Malignant Mesothelioma Treatment Market Overview, By Application, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.4.1.3. Other Segments
10.1.4.2. China
10.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.2.2. China Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.4.2.3. Other Segments
10.1.4.3. Japan
10.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.4.3.3. Other Segments
10.1.4.4. South Korea
10.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.4.2. South Korea Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.4.4.3. Other Segments
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
10.1.4.5.3. Other Segments
Chapter 11. Middle East & Africa Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Malignant Mesothelioma Treatment Market Overview, By Application, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.4.1.3. Other Segments
11.1.4.2. South Africa
11.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.4.2.3. Other Segments
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
11.1.4.3.3. Other Segments
Chapter 12. South America Malignant Mesothelioma Treatment Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Malignant Mesothelioma Treatment Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. South America Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.3. South America Malignant Mesothelioma Treatment Market Overview, By Application, 2015 - 2027 (USD Million)
12.1.4. South America Malignant Mesothelioma Treatment Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.5. Brazil
12.1.5.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.2. Brazil Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.5.3. Other Segments
12.1.6. Argentina
12.1.6.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.6.2. Argentina Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.6.3. Other Segments
12.1.7. Rest of South America
12.1.7.1. Market size and projections, 2015 – 2027
12.1.7.2. Rest of South America Malignant Mesothelioma Treatment Market Overview, By Drug Class, 2015 - 2027 (USD Million)
12.1.7.3. Other Segments
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Distribution channel development
Chapter 14. Key Vendor Analysis
14.1. Eli Lilly
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Distribution channel Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. AstraZeneca plc
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Distribution channel Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Bristol-Myers Squibb Company
14.4. Boehringer Ingelheim GmbH
14.5. Epizyme, Inc
14.6. Others
Chapter 15. Malignant Mesothelioma Treatment Market Cost Analysis
15.1. Malignant Mesothelioma Treatment Market Key Raw Application Analysis
15.1.1. Key Raw Application
15.1.2. Price Trend of Key Raw Application
15.1.3. Key Suppliers of Raw Application
15.1.4. Market Concentration Rate of Raw Application
Chapter 16. Industrial Chain, Sourcing Strategy and Downstream Buyers
16.1. Malignant Mesothelioma Treatment Market Industrial Chain Analysis
16.2. Upstream Raw Application Sourcing
16.3. Raw Application Source of Malignant Mesothelioma Treatment Market Major Manufacturers in 2021
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target PERITONEAL MESOTHELIOMA
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Technology Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Technology Progress in Related Distribution channel
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer
List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Engine Powered of Suppliers
5. Engine Powered of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Malignant Mesothelioma Treatment Market share, By Drug Class, 2020 & 2027 (%)
10. Global Malignant Mesothelioma Treatment Market share, by ALKYLATING AGENTS, By Drug Class, 2020 & 2027 (USD Million)
11. Global Malignant Mesothelioma Treatment Market share, by ANTIMETABOLITES, By Drug Class, 2020 & 2027 (USD Million)
12. Global Malignant Mesothelioma Treatment Market share, by PLANT ALKALOIDS, By Drug Class, 2020 & 2027 (USD Million)
13. Global Malignant Mesothelioma Treatment Market share, By Application, 2020 & 2027 (%)
14. Global Malignant Mesothelioma Treatment Market share, by PERITONEAL MESOTHELIOMA, By Application, 2020 & 2027 (USD Million)
15. Global Malignant Mesothelioma Treatment Market share, by Pleural Mesothelioma,, By Application, 2020 & 2027 (USD Million)
16. Global Malignant Mesothelioma Treatment Market share, by Region, 2020 & 2027 (%)
17. Global Malignant Mesothelioma Treatment Market share, by region, 2020 - 2027(USD Million)
18. North America Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
19. North America Malignant Mesothelioma Treatment Market share, by Countries, 2020 & 2027 (%)
20. U.S. Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
21. Canada Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
22. Europe Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
23. Europe Malignant Mesothelioma Treatment Market share, by Countries, 2020 & 2027 (%)
24. Spain Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
25. UK Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
26. Italy Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
27. Germany Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
28. France Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
29. Rest of Europe Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
30. Asia-Pacific Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
31. Asia-Pacific Malignant Mesothelioma Treatment Market share, by Countries, 2020 & 2027 (%)
32. China Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
33. India Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
34. Australia Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
35. Japan Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
36. Rest of Asia-Pacific Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
37. Middle East & Africa Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
38. Middle East & Africa Malignant Mesothelioma Treatment Market share, by Countries, 2020 & 2027 (%)
39. GCC Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
40. South Africa Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
41. Rest Of Middle East & Africa Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
42. South America Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
43. Brazil Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
44. Mexico Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
45. Argentina Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
46. Rest Of South America Malignant Mesothelioma Treatment Market, 2020 - 2027(USD Million)
List of Tables
1. Impact of Market drivers
2. Impact of Market restraints
3. Global Malignant Mesothelioma Treatment Market, 2020-2027 (USD Million)
4. Malignant Mesothelioma Treatment requirement, by country, 2020-2027, (USD Million)
5. North America Malignant Mesothelioma Treatment Market, By Drug Class, 2020-2027 (USD Million)
6. North America Malignant Mesothelioma Treatment Market, By Application, 2020-2027 (USD Million)
7. North America Malignant Mesothelioma Treatment Market, By End use industry, 2020-2027 (USD Million)
8. Europe Malignant Mesothelioma Treatment Market, By Drug Class, 2020-2027 (USD Million)
9. Europe Malignant Mesothelioma Treatment Market, By Application, 2020-2027 (USD Million)
10. Europe Malignant Mesothelioma Treatment Market, By End use industry, 2020-2027 (USD Million)
11. Asia Pacific Malignant Mesothelioma Treatment Market, By Drug Class, 2020-2027 (USD Million)
12. Asia Pacific Malignant Mesothelioma Treatment Market, By Application, 2020-2027 (USD Million)
13. Asia Pacific Malignant Mesothelioma Treatment Market, By End use industry, 2020-2027 (USD Million)
14. Middle East & Africa Malignant Mesothelioma Treatment Market, By Drug Class, 2020-2027 (USD Million)
15. Middle East & Africa Malignant Mesothelioma Treatment Market, By Application, 2020-2027 (USD Million)
16. Middle East & Africa Malignant Mesothelioma Treatment Market, By End use industry, 2020-2027 (USD Million)
17. South America Malignant Mesothelioma Treatment Market, By Drug Class, 2020-2027 (USD Million)
18. South America Malignant Mesothelioma Treatment Market, By Application, 2020-2027 (USD Million)
19. South America Malignant Mesothelioma Treatment Market, By End use industry, 2020-2027 (USD Million)
20. Global Malignant Mesothelioma Treatment Market, Company Market Share, 2020 & 2027(%)
21. Eli Lilly: Pleural Mesothelioma, Benchmarking
22. Eli Lilly: Financial Performance
23. AstraZeneca plc: Pleural Mesothelioma, Benchmarking
24. AstraZeneca plc : Financial Performance
25. Bristol-Myers Squibb Company: Pleural Mesothelioma, Benchmarking
26. Bristol-Myers Squibb Company: Financial Performance
27. Boehringer Ingelheim GmbH: Pleural Mesothelioma, Benchmarking
28. Boehringer Ingelheim GmbH: Financial Performance
29. Epizyme, Inc: Pleural Mesothelioma, Benchmarking
30. Epizyme, Inc: Financial Performance
The Leading Key Players in Malignant Mesothelioma Treatment Market
Eli Lilly and Company
AstraZeneca plc
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Epizyme Inc
Bayer AG
Aduro Biotech
Ono Pharmaceutical Co. Ltd.
Polaris Pharmaceuticals Inc.
Calithera Biosciences Inc.
CBT Pharmaceuticals Inc.
